After a rollercoaster ride, the US NDA for Ocular Therapeutix Inc.’s eye insert, Dextenza (dexamethasone), has been accepted for review by the FDA for the treatment of ocular pain after ophthalmic surgery, and the company believes there is a significant market opportunity for the extended-release product, its lead product.
The NDA acceptance, and the setting of a PDUFA date of July 19, 2017, represents a turnaround for the company...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
